reports
- Dylan Van Haaften
- Edward Hall
ONWARD MEDICAL BUY | EUR17 The Up-LIFT we have been waiting for
This morning ONWARD’s reported pivotal Up-LIFT trial using ARCEX external Neurostimulation attained its primary endpoint at a clinical relevant threshold. This positive top-line data (stat. sig. in one function and strength endpoint) in the restoration of arm and hand function in patients paralysed in four limbs is likely to be filed in coming months, with further data being disclosed imminently. With key catalysts upcoming like i) Up-LIFT data presentation in the coming months, ii) observationa...
- Edward Hall
- Edward Hall
- Edward Hall
- Dylan Van Haaften
- Edward Hall
Onward Medical Initiation of coverage BUY, EUR17 Get Up, Stand Up
We are initiating Onward Medical with a BUY rating and a EUR 17 price target. Onward Medical is a clinical, soon to be commercial, Swiss-Dutch MedTech company developing two groundbreaking neuromodulating platforms for the treatment of spinal cord injury (SCI). The two platforms that the company is developing are the ARCEX, a non-invasive platform for the treatment of upper extremity restoration and the higher value ARCIM an implantable platform with initial focus on blood pressure and trunk con...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.